Stockscreener 앱 받기
0.8485
1.13%
0.0095
전일 마감가:
$0.839
열려 있는:
$0.8444
하루 거래량:
65,016
Relative Volume:
0.02
시가총액:
$8.42M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-9.45%
1개월 성능:
-57.79%
6개월 성능:
-88.20%
1년 성능:
+0.00%
1일 변동 폭
$0.8035
$0.8914
1주일 범위
$0.8035
$0.9366
52주 변동 폭
$0.69
$9.55
Scienture Holdings Inc Stock (SCNX) Company Profile
명칭
Scienture Holdings Inc
전화
(800) 261 0281
주소
2420 BRUNELLO TRACE, LUTZ
SCNX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SCNX
Scienture Holdings Inc
|
0.8485 | 8.42M | 0 | 0 | 0 | 0.00 |
|
WBA
Walgreens Boots Alliance Inc
|
10.97 | 9.38B | 147.66B | -8.64B | -363.00M | -10.01 |
|
WGRX
Wellgistics Health Inc
|
3.30 | 204.66M | 0 | 0 | 0 | 0.00 |
|
HITI
High Tide Inc
|
2.295 | 178.87M | 376.07M | -22.41M | 18.73M | -0.298 |
|
PETS
Petmed Express Inc
|
3.115 | 62.18M | 270.52M | -6.08M | 17.42M | -0.2944 |
|
HKPD
Hong Kong Pharma Digital Technology Holdings Ltd
|
0.96 | 13.20M | 0 | 0 | 0 | 0.00 |
Scienture Holdings Inc 주식(SCNX)의 최신 뉴스
Scienture Announces Manufacturing And Supply Chain Readiness For ArbliTM, (Losartan Potassium) Oral Suspension, 10Mg/Ml For A Target Product Launch In July 2025 - marketscreener.com
SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025. - The Manila Times
SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025. | SCNX Stock News - GuruFocus
Revolutionary Liquid Losartan Targets $292M Market: First FDA-Approved Formula Challenges Traditional Tablets - Stock Titan
Scienture Holdings Divests Subsidiaries to Tollo Health - MSN
Scienture Holdings divests subsidiaries for $5 million By Investing.com - Investing.com South Africa
Scienture divests Integra Pharma Solutions, Bonum Health, Softell for $5M - TipRanks
Scienture Sells 3 Subsidiaries to Tollo Health for $5 Million - MarketScreener
Scienture Announces The Divestiture Of Its Legacy Subsidiaries - MarketScreener
Scienture Holdings divests subsidiaries for $5 million - Investing.com
SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC. - The Manila Times
Strategic Pivot: Scienture Sells Healthcare IT Units for $5M, Doubles Down on Specialty Pharma - Stock Titan
SCNX stock touches 52-week low at $0.97 amid market challenges - Investing.com Canada
Scienture Holdings Files Prospectus Relates To Resale From Time To Time Of Up To 2.6 Million Shares Of Common Stock By Selling Stockholders - marketscreener.com
SCNX stock touches 52-week low at $0.97 amid market challenges By Investing.com - Investing.com South Africa
Scienture Holdings gears up for specialty pharma launches - Investing.com
Scienture CEO says focused on execution, growth, expansion for years ahead - TipRanks
Scienture Holdings gears up for specialty pharma launches By Investing.com - Investing.com UK
Scienture Holdings, Inc. Issues Annual Letter to Shareholders - TradingView
Investors: What’s The Real Deal With Scienture Holdings Inc (NASDAQ: SCNX) - Stocks Register
Scienture Bolsters Commercial Operations with New Leadership and Syneos Health Partnership - AInvest
SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization - The Manila Times
Scienture Gears Up for Major Product Launch: New CCO and Syneos Health Partnership Signal Growth - Stock Titan
3 Reasons APG is Risky and 1 Stock to Buy Instead - The Globe and Mail
Scienture Holdings Announces FDA Approval for ArbliTM - TipRanks
Lucid (LCID): Buy, Sell, or Hold Post Q4 Earnings? - The Globe and Mail
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Scienture Holdings announces draw on Equity Line of Credit - MSN
Scienture announces draaw on Equity Line of Credit - TipRanks
Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days - The Manila Times
Organovo Announces Reverse Stock Split - The Manila Times
FDA Approves Revolutionary Liquid Losartan: Scienture's Game-Changing Hypertension Treatment - StockTitan
Scienture announces U.S. FDA approval of NDA for SCN-102 - TipRanks
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
FDA Approves Losartan Potassium for Reduction in Risk of Stroke - Drug Topics
What's Going On With Scienture Shares Tuesday? - Benzinga
FDA Approves SCN-102, Liquid Oral Suspension Formulation of Losartan - Pharmacy Times
Pre-Market Momentum: Scienture (SCNX) Stock Soars After FDA Green Light - Stocks Telegraph
Scienture Says US FDA Approves Oral Liquid Formulation of Hypertension Drug Losartan - MarketScreener
SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024. - The Manila Times
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Breakthrough FDA Approval: First-Ever Liquid Hypertension Drug Targets $1.5B Market - StockTitan
Billionaires Ray Dalio and Paul Tudor Jones Are Piling Into a Hard Asset That Has Trounced Nvidia This Year - The Globe and Mail
Q4 Earnings Outperformers: D.R. Horton (NYSE:DHI) And The Rest Of The Home Builders Stocks - The Globe and Mail
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Scienture Holdings Inc (SCNX) Stock Behavior Isn’t As Predictable As You Think - Stocks Register
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Scienture Holdings appoints new CFO, stockholders vote at annual meeting By Investing.com - Investing.com Australia
Scienture Holdings appoints new CFO, stockholders vote at annual meeting - Investing.com
Scienture Holdings Appoints New CFO Eric Sherb - TipRanks
Scienture Holdings Inc (SCNX) 재무 분석
Scienture Holdings Inc (SCNX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.33%
3.84%
자본화:
|
볼륨(24시간):